

References

1. Tanner CM, Golman SM. Epidemiology of Parkinson's Disease. *Neurol Clin* 1996; 14: 317-35.
2. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's Disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. *Am J Epidemiol* 1995; 142: 820-7.
3. de Rijk MC, Tzourio C, Breteler MMB, et al. Prevalence of parkinsonism and Parkinson's Disease in Europe: The EUROPARKINSON collaborative study. *J Neurol Neurosurg Psychiatry* 1997; 62: 10-5.
4. Scheife RT, Schumock GT, Burstein A, et al. Impact of Parkinson's Disease and its pharmacologic treatment on quality of life and economic outcomes. *Am J Health-Syst Pharm* 2000; 57: 953-62.
5. Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's Disease: An updated review. *Neuroepidemiology* 1993; 12: 195-208.
6. Louis ED, Marder K, Cote L, et al. Mortality from Parkinson Disease. *Arch Neurol* 1997; 54: 260-4.
7. Berchou RC. Maximizing the benefit of pharmacotherapy in Parkinson's Disease. *Pharmacotherapy* 2000; 20: 33S-42S.
8. Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson's Disease. *Pharmacoeconomics* 1998; 14: 299-312.
9. Agid Y, Ruberg M, Javoy-Agid F, et al. Are dopaminergic neurons selectively vulnerable to Parkinson's Disease? *Adv Neurol* 1993; 60: 148-64.
10. Prasad KN, Cole WC, Kumar B. Multiple antioxidants in the prevention and treatment of Parkinson's Disease. *J Am Coll Nutr* 1999; 18: 413-23.
11. Stoof JC, Winogrodzka A, van Muiswinkel FL, et al. Leads for the development of neuroprotective treatment in Parkinson's Disease and brain imaging methods for estimating treatment efficacy. *Eur J Pharmacol* 1999; 375: 75-86.
12. Riess O, Jakes R, Kruger R. Genetic dissection of familial Parkinson's Disease. *Mol Med Today* 1998; 4: 438-44.
13. Veldman BA, Wijn AM, Knoers N, et al. Genetic and environmental risk factors in Parkinson's Disease. *Clin Neurol Neurosurg* 1998; 100: 15-26.
14. Williams AC, Smith ML, Waring RH, et al. Idiopathic Parkinson's Disease: A genetic and environmental model. *Adv Neurol* 1999; 80: 215-8.
15. Racette BA, McGee-Minnich L, Moerlein SM, et al. Welding-related parkinsonism. Clinical features, treatment, and pathophysiology. *Neurology* 2001; 56: 8-13.
16. Semchuk KKM, Love EJ, Lee RG. Parkinson's Disease and exposure to agricultural work and pesticide chemicals. *Neurology* 1992; 42: 1328-35.
17. Hellenbrand W, Seidler A, Robra BP, et al. Smoking and Parkinson's Disease: A case-control study in Germany. *Int J Epidemiol* 1997; 26: 328-39.
18. Morens DM, Grandinetti A, Davis JW, et al. Evidence against the operation of selective mortality in explaining association between cigarette smoking and reduced occurrence of idiopathic Parkinson Disease. *Am J Epidemiol* 1996; 144: 400-4.
19. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson's Disease. *JAMA* 2000; 283: 2674-9.
20. Tzourio C, Rocca WA, Breteler MMB, et al. Smoking and Parkinson's Disease: An age-

- dependent risk effect? *Neurology* 1997; 49: 1267-72.
21. Shults CW, Haas RH, Beal MF. A possible role of coenzyme Q₁₀ in the etiology and treatment of Parkinson's Disease. *Biofactors* 1999; 9: 267-72.
 22. de Rijk MC, Breteler MMB, den Breeijen JH, et al. Dietary antioxidants and Parkinson Disease: The Rotterdam Study. *Arch Neurol* 1997; 54: 762-5.
 23. Hellenbrand W, Boeing H, Robra BP, et al. Diet and Parkinson's Disease II: A possible role for past intake of specific nutrients. Results from a self administered food-frequency questionnaire in a case-control study. *Neurology* 1996; 47: 644-50.
 24. Logroscino G, Marder K, Cote T, et al. Dietary lipids and antioxidants in Parkinson's Disease: a population-based, case-control study. *Ann Neurol* 1996; 39: 89-94.
 25. Hellenbrand W, Seidler A, Boeing H, et al. Diet and Parkinson's Disease I: A possible role for past intake of specific foods and food groups. Results from a self administered food-frequency questionnaire in a case-control study. *Neurology* 1996; 47: 636-42.
 26. Gelb DJ, Oliver E, Gilman S. Diagnostic Criteria for Parkinson Disease. *Arch Neurol* 1999; 56: 33-9.
 27. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's Disease. *Ann Neurol* 1992; 32: S125-7.
 28. Hornykiewicz O. Parkinson's Disease and its chemotherapy. *Biochem Pharmacol* 1975; 24: 1061-5.
 29. Hely MA, Fung VSC, Morris JGL. Treatment of Parkinson's Disease. *J Clin Neurosci* 2000; 7: 484-94.
 30. Stroudley J, Walsh M. Radiological assessment of dysphagia in Parkinson's Disease. *Br J Radiol* 1991; 64: 890-3.
 31. Ramig LO, Countryman S, O'Brien C, et al. Intensive speech treatment for patients with Parkinson's Disease: Short- and long-term comparison of two techniques. *Neurology* 1996; 47: 1496-504.
 32. Ramig LO, Sapir S, Fox C, et al. Changes in vocal loudness following intensive voice treatment in individuals with Parkinson's Disease: A comparison with untreated patients and normal age-matched controls. *Mov Disord* 2001; 16: 79-83.
 33. Schulz GM, Grant MK. Effects of speech therapy and pharmacologic and surgical treatments on voice and speech in Parkinson's Disease: A review of the literature. *J Commun Disord* 2000; 33: 59-88.
 34. Razmy A, Shapiro CM. Interactions of sleep and Parkinson's Disease. *Semin Clin Neuropsychiatry* 2000; 5: 20-32.
 35. Marsh L. Neuropsychiatric aspects of Parkinson's Disease. *Psychosomatics* 2000; 41: 15-23.
 36. Mindham RHS. The place of dementia in Parkinson's Disease: A methodologic saga. *Parkinson's Disease: Advances in Neurology* 1999; 80: 403-8.
 37. Reid WGJ, Hely MA, Morris JGL, et al. A longitudinal study of Parkinson's Disease: Clinical and neuropsychological correlates of dementia. *J Clin Neurosci* 1996; 3: 327-33.
 38. Katzen HL, Levin BE, Llabre ML. Age of disease onset influences cognition in Parkinson's Disease. *J Int Neuropsychol Soc* 1998; 4: 285-90.
 39. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's Disease: A quantitative and qualitative analysis. *J Neurol Neurosurg Psychiatry* 1986; 49: 381-9.
 40. Ward CD, Gibb WR. Research diagnostic criteria for Parkinson's Disease. *Adv Neurol* 1990; 53: 245-9.
 41. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's Disease. *J Neurol Neurosurg Psychiatry* 1988; 51: 745-52.

42. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. *J Neurol Neurosurg Psychiatry* 1992; 55: 1142-6.
43. Hughes AJ, Ben-Shlomo Y, Daniel SE. What features improve the accuracy of clinical diagnosis in Parkinson's Disease: A clinicopathologic study. *Neurology* 1992; 42: 1142-6.
44. Rajput AH, Rodzilsky B, Rajput A. Accuracy of clinical diagnosis of Parkinsonism - a prospective study. *Can J Neurol Sci* 1991; 18: 275-8.
45. Clarke CE, Davies P. Systematic review of acute L-dopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's Disease. *J Neurol Neurosurg Psychiatry* 2000; 69: 590-4.
46. Brooks DJ. PET and SPECT studies in Parkinson's Disease. *Baillieres Clin Neurol* 1997; 6: 69-87.
47. Antonini A, Leenders KL, Meier D, et al. T₂ relaxation time in patients with Parkinson's Disease. *Neurology* 1993; 43: 697-700.
48. Wszolek ZK, Markopoulou K. Olfactory dysfunction in Parkinson's Disease. *Clin Neurosci*. 1998; 5: 94-101.
49. Liberini P, Parola S, Spano PF, et al. Olfaction in Parkinson's Disease: Methods of assessment and clinical relevance. *J Neurol* 2000; 247: 88-96.
50. Meshulam RI, Moberg PJ, Mahr RN, et al. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's Diseases. *Arch Neurol* 1998; 55: 84-90.
51. Horstink MW and Morrish PK. Preclinical diagnosis of Parkinson's Disease. *Parkinson's Disease: Advances in Neurology*. vol 80, 1999, Philadelphia: Lippincott Williams & Wilkins, pp. 327-33.
52. Stacy M, Jankovic J. Differential diagnosis of Parkinson's Disease and the Parkinsonism plus syndromes. *Neurol Clin* 1992; 10: 341-59.
53. Fahn S, Marsden CD, Calne DB, et al., eds. *Recent Developments in Parkinson's Disease*. vol 2. Florham Park, NJ. MacMillan Health Care Information 1987; pp 153-63, 293-304.
54. Martinez-Martin P, Fontan C, Payo BF, et al. Parkinson's Disease: Quantification of disability based on the Unified Parkinson's Disease Rating Scale. *Neurologia* 2000; 15: 382-7.
55. Martinez-Martin P, Gil-Nagel A, Gracia LM, et al. Unified Parkinson's Disease Rating Scale characteristics and structure. *Mov Disord* 1994; 9: 76-83.
56. Hoehn MM and Yahr MD. Parkinsonism: Onset, progression, and mortality. *Neurology* 1967; 17: 427-442.
57. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's Disease. In Gillingham FJ, Donaldson IML, eds. *Third Symposium of Parkinson's Disease*. Edinburgh, Scotland: E&S Livingstone; 1969. p 152-7.
58. Lang AE, Lozano AM. Parkinson's Disease: Second of two parts. *N Engl J Med* 1998; 339: 1130-43.
59. Hauser RA, Zesiewicz TA. Management of early Parkinson's Disease. *Med Clin North Am* 1999; 83: 393-414.
60. Simon DK, Standaert DG. Parkinson's Disease and parkinsonian syndromes: Neuroprotective therapies. *Med Clin North Am* 1999; 83: 509-23.
61. Stacy M. Managing late complications of Parkinson's Disease. *Med Clin North Am* 1999; 83: 469-81.
62. Fehling C. Treatment of Parkinson's syndrome with L-dopa. A double blind study. *Acta Neurol Scand* 1966; 42: 367-72.
63. Pincus JH, Barry K. Influence of dietary protein on motor fluctuations in Parkinson's Disease. *Arch Neurol* 1987; 44: 270-2.

64. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's Disease. *Brain* 2000; 123: 2297-305.
65. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's Disease who were treated with ropinirole or levodopa. *N Engl J Med* 2000; 342: 1484-91.
66. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson's Disease: A randomized controlled trial. *JAMA* 2000; 284: 1931-8.
67. Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson's Disease: A consensus meeting. *Mov Disord* 1999; 14: 911-13.
68. Jankovic J. New and emerging therapies for Parkinson Disease. *Arch Neurol* 1999; 56: 785-90.
69. Mendis T, Suchowersky O, Lang A, et al. Management of Parkinson's Disease: A review of current and new therapies. *Can J Neurol Sci* 1999; 26: 89-103.
70. Fahn S. Parkinson Disease, the effect of levodopa, and the ELLDOPA trial. *Arch Neurol* 1999; 56: 529-35.
71. Calne DB, Teychenne PF, Leigh PHN, et al. Treatment of parkinsonism with bromocriptine. *Lancet* 1974; 2: 1355-6.
72. Ramaker C, Johan WT, van de Beek, MS. The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications: A systematic review. *Mov Disord* 2000; 15: 56-64.
73. van Hilten JJ, Ramaker C, van de Beek WJT, et al. Bromocriptine for levodopa-induced motor complications in Parkinson's Disease (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2000. Oxford: Update Software.
74. Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson's Disease should begin with a dopamine agonist. *Mov Disord* 1999; 14: 725-30.
75. Factor SA. Dopamine agonists. *Med Clin North Am.* 1999; 83: 415-43.
76. Clarke CE, Speller JM. Pergolide for levodopa-induced complications in Parkinson's Disease (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2000. Oxford: Update Software.
77. Clarke CE, Speller JM. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's Disease (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2000. Oxford: Update Software.
78. Clarke CE, Speller JM. Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's Disease (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2000. Oxford: Update Software.
79. Clarke CE, Speller JM. Lisuride for levodopa-induced complications in Parkinson's Disease (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2000. Oxford: Update Software.
80. Snow BJ, Macdonald L, Mcauley D, et al. The effect of amantadine of levodopa-induced dyskinesias in Parkinson's Disease: A double-blind, placebo-controlled study. *Clin Neuropharmacol* 2000; 23: 82-5.
81. Shoulson I and Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). *Acta Neurol Scand* 1989; 126: 171-5.
82. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's Disease. *N Engl J Med* 1993; 328: 176-83.
83. Tatton WG, Wadia JS, Ju WY, et al. Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. *J Neural Transm* 1996; 48: 45-59.
84. Magyar K, Haverle D. Neuroprotective and neuronal rescue effects of selegiline. *Neurobiology* 1999; 7: 175-90.

85. Jorga K, Fotteler B, Sedek G, et al. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. *J Neurol* 1998; 245: 223-30.
86. Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial. *Neurology* 1997; 49: 1066-71.
87. Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis. *Lancet* 1998; 352: 1478.
88. Olanow CW. Tolcapone and hepatotoxic effects. Tasmal Advisory Panel. *Arch Neurol* 2000; 57: 263-7.
89. Martin WE, Loewenson RB, Resch JA, et al. A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's Disease. *Neurology* 1974; 24: 912-9.
90. Miller E, Berrios GE, Politynska B. The adverse effect of benzhexol on memory in Parkinson's Disease. *Acta Neurol Scand* 1987; 76: 278-82.
91. Idanpaan-Heikkila J, Alhava E, Olkinuora M, et al. Agranulocytosis during treatment with clozapine. *Eur J Clin Pharmacol* 1977; 11: 193-8.
92. Lieberman JA, Johns CA, Kane JM, et al. Clozapine-induced agranulocytosis: Non-cross-reactivity with other psychotropic drugs. *J Clin Psychiatry* 1988; 49:271-7.
93. Selby G. Stereotactic surgery for the relief of Parkinson's Disease. *J Neurol Sci* 1967; 5: 343-75.
94. Arle JE, Alterman RL. Surgical options in Parkinson's Disease. *Med Clin North Am* 1999; 83: 483-98.
95. Uitti RJ. Surgical treatments for Parkinson's Disease. *Can Fam Phys* 2000; 46: 368-73.
96. Bronstein JM, DeSalles A, DeLong MR. Stereotactic pallidotomy in the treatment of Parkinson's Disease: An expert opinion. *Arch Neurol* 1999; 56: 1064-9.
97. Hallett M, Litvan I. Evaluation of surgery for Parkinson's Disease: A report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 1999; 53: 1910-21.
98. Lozano AM, Lang AE, Galvez-Jiminez N, et al. Effect of GPi pallidotomy on motor function in Parkinson's Disease. *Lancet* 1995; 346: 1383-7.
99. Fields JA, Troster AI. Cognitive outcomes after deep brain stimulation for Parkinson's Disease: A review of initial studies and recommendations for future research. *Brain Cogn* 2000; 42: 268-93.
100. Schuurman PR, Bosch DA, Bossuyt PMM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. *N Eng J Med* 2000; 342: 461-8.
101. Koller WC, Pahwa R, Lyons KE, et al. Surgical treatment of Parkinson's Disease. *J Neurol Sci* 1999; 167: 1-10.
102. Backlund EO, Granberg PO, Hamberger B, et al. Transplantation of adrenal medullary tissue to striatum in parkinsonism: First clinical trials. *J Neurosurg* 1985; 62: 169-73.
103. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's Disease. *N Engl J Med* 2001; 344: 710-9.
104. Langston JW, Widner H, Goetz CG, et al. Core Assessment Program for Intracerebral Transplantations. *Mov Disord* 1992; 7: 2-13.
105. Defer GL, Widner H, Marie RM, et al. Core Assessment Program for Surgical Interventional Therapies in Parkinson's Disease (CAPSIT-PD). *Mov Disord* 1999; 14: 572-84.
106. Clarke CE, Zobkiw RM. Quality of life and care in Parkinson's Disease. *Brit J Clin Pract* 1995; 49: 288-93.
107. Hildick-Smith M. Pragmatic physical therapy in Parkinson's Disease: Any

- scientific basis? Parkinson's Disease: Advances in Neurology 1999; 80: 561-4.
108. Johnson JA, Pring TR. Speech therapy and Parkinson's Disease: A review and further data. Br J Disord Commun 1990; 25: 183-94.
109. Johnson BT, Qun L, Castell JA, et al. Swallowing and esophageal function in Parkinson's Disease. Amer J Gastroenterol 1995; 90: 1741-6.
110. Mulrow C, Cook DJ, Davidoff F. Systematic reviews: critical links in the great chain of evidence. Ann Intern Med 1997; 126: 389-91.
111. Sacks HS, Berrier J, Reitman D, et al. Meta-analyses of randomized controlled trials. N Engl J Med 1987; 316: 450-5.
112. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials 1996; 17: 1-12.
113. Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 1998: 158.
114. Hely MA, Chey T, Wilson A, et al. Reliability of the Columbia scale for assessing signs of Parkinson's Disease. Mov Disord 1993; 8: 466-72.
115. Canter GJ, deLaTorre R, Mier M. A method for evaluating disability in patients with Parkinson's Disease. J Nerv Ment Dis 1961; 133: 143-7.
116. Hedges L, Olkin I. Statistical Methods for Meta-Analysis. 1985. New York: Academic Press.
117. Raudenbush SW. The Handbook of Research Synthesis. New York: Russell Sage Foundation; 1994. Chapter 20, Random Effects Models.
118. Hedges LV. The Handbook of Research Synthesis. New York: Russell Sage Foundation; 1994. Chapter 19, Fixed Effects Models.
119. Bromocriptine Multicentre Trial Group. Bromocriptine as initial therapy in elderly parkinsonian patients. Age Aging 1990; 19: 62-7.
120. Irwig L, Tosteson ANA, Gatsonis C, et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med 1994; 120: 667-76.
121. D'Costa DF, Abbot RJ, Pye IF, et al. The apomorphine test in parkinsonian syndromes. J Neurol Neurosurg Psychiatry 1991; 10: 870-2.
122. Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 1990; 336: 32-4.
123. Hughes AJ, Lees AJ, Stern GM. Challenge tests to predict the dopaminergic response in untreated Parkinson's Disease. Neurology 1991; 41: 1723-5.
124. Gasser T, Schwarz J, Arnold G, et al. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's Disease. Arch Neurol 1992; 49: 1131-4.
125. Bonucelli U, Picini P, Del Dotto P, et al. Apomorphine test for dopaminergic responsiveness: A dose assessment study. Mov Disord 1993; 8: 158-64.
126. Schwarz J, Linke R, Kerner M, et al. Striatal dopamine transporter binding assessed by [¹²³I]-IPT and single photon emission computed tomography in patients with early Parkinson' Disease: Implications for a preclinical diagnosis. Arch Neurol 2000; 57: 205-8.
127. Schwarz J, Kraft E, Vogl T, et al. Relative quantification of signal on T2-weighted images in the basal ganglia: Limited value in differential diagnosis of patients with parkinsonism. Neuroradiology 1999; 41: 124-7.
128. Schwarz J, Tatsch K, Gasser T, et al. ¹²³I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord 1998; 13: 16-9.

129. Schwarz J, Antonini A, Tatsch K, et al. Comparison of ^{123}I -IBZM SPECT and ^{11}C -raclopride PET findings in patients with parkinsonism. *Nucl Med Commun* 1994; 15: 806-13.
130. Schwarz J, Tatsch K, Arnold G, et al. ^{123}I -iodobenzamide-SPECT in 83 patients with de novo parkinsonism. *Neurology* 1993; 43: S17-20.
131. Schwarz J, Tatsch K, Gasser T, et al. [^{123}I]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. *Mov Disord* 1997; 12: 898-902.
132. Schelosky L, Hierholzer J, Wissel J, et al. Correlation of clinical response in apomorphine test with D_2 receptor status as demonstrated by ^{123}I IBZM-SPECT. *Mov Disord* 1993; 8: 453-8.
133. Booij J, Tissingh G, Boer GJ, et al. [^{123}I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's Disease. *J Neurol Neurosurg Psychiatry* 1997; 62: 133-40.
134. Tatsch K, Schwarz J, Oertel WH, et al. SPECT imaging of dopamine D_2 receptors with ^{123}I -IBZM: Initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. *Nucl Med Commun* 1991; 12: 699-707.
135. Giobbe D, Castellano GC, Podio V. Dopamine D_2 receptor imaging with SPECT using IBZM in 16 patients with Parkinson's Disease. *Ital J Neurol Sci* 1993; 14: 165-9.
136. Pizzolato G, Cagnin A, Rossato A, et al. Striatal dopamine D_2 receptor alterations and response to L-dopa in Parkinson's Disease. *Adv Neurol* 1996; 69: 467-73.
137. Imon Y, Matsuda H, Ogawa M, et al. SPECT image analysis using statistical parametric mapping in patients with Parkinson's Disease. *J Nucl Med* 1999; 40: 1583-9.
138. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [^{123}I]β-CIT striatal uptake correlates with symptom severity in Parkinson's Disease. *Ann Neurol* 1995; 38: 589-98.
139. Kaasinen V, Nagren K, Hietala J, et al. Extrastriatal dopamine D_2 and D_3 receptors in early and advanced Parkinson's Disease. *Neurology* 2000; 54: 1482-7.
140. Rinne JO, Portin R, Ruottinen H, et al. Cognitive impairment and the brain dopaminergic system in Parkinson's Disease: [^{18}F]fluorodopa positron emission tomographic study. *Arch Neurol* 2000; 57: 470-5.
141. Rinne JO, Laihin A, Ruottinen H, et al. Increased density of dopamine D_2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's Disease: A PET study with [^{11}C] raclopride. *J Neurol Sci* 1995; 132: 156-61.
142. Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson's Disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal ^{18}F -dopa PET data. *J Neurol Neurosurg Psychiatry* 1994; 57: 278-84.
143. Morrish PK, Sawle GV, Brooks DJ. Clinical and [^{18}F] dopa PET findings in early Parkinson's Disease. *J Neurol Neurosurg Psychiatry* 1995; 59: 597-600.
144. Sawle GV, Playford ED, Burn DJ, et al. Separating Parkinson's Disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. *Arch Neurol* 1994; 51: 237-43.
145. Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson's Disease with ^{18}F -fluorodeoxyglucose and positron emission tomography. *Neurology* 1995; 45: 1995-2004.
146. Otsuka M, Ichiya Y, Hosokawa S, et al. Striatal blood flow, glucose metabolism and ^{18}F -Dopa uptake: Difference in Parkinson's Disease and atypical parkinsonism. *J Neurol Neurosurg Psychiatry* 1991; 54: 898-904.

147. Kraft E, Schwarz J, Trenkwalder C, et al. The combination of hypointense and hyperintense signal changes on T₂-weighted magnetic resonance imaging sequences: A specific marker of multiple system atrophy? *Arch Neurol* 1999; 56: 225-8.
148. Ryvlin P, Broussole E, Piollet H, et al. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's Disease. *Arch Neurol* 1995; 52: 583-8.
149. Holshouser BA, Komu M, Moller HE, et al. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's Disease: A multicenter pilot study. *Magn Reson Med* 1995; 33: 589-94.
150. Becker G, Seufert J, Bogdahn U, et al. Degeneration of substantia nigra in chronic Parkinson's Disease visualized by transcranial color-coded real-time sonography. *Neurology* 1995; 45: 182-4.
151. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's Disease. *Age Ageing* 1999; 28: 99-102.
152. Jankovic J, Rajput AH, McDermott MP, et al. The evolution of diagnosis in early Parkinson Disease. *Arch Neurol* 2000; 57: 369-72.
153. Buttner T, Kuhn W, Muller T, et al. Distorted color discrimination in de novo parkinsonian patients. *Neurology* 1995; 45: 386-7.
154. Buttner T, Kuhn W, Patzold T, et al. L-dopa improves color vision in Parkinson's Disease. *J Neural Transm* 1994; 7: 13-9.
155. Delalande I, Destee A, Hache JC, et al. Visual evoked potentials and spatiotemporal contrast sensitivity changes in idiopathic Parkinson's Disease and multiple system atrophy. *Adv Neurol* 1996; 69: 319-25.
156. Relja MA, Petravic D, Kolaj M. Quantifying rigidity with a new computerized elbow device. *Clin Neuropharmacol* 1996; 19: 148-56.
157. Fung VSC, Burne JA, Morris JGL. Objective quantification of resting and activated parkinsonian rigidity: A comparison of angular impulse and work scores. *Mov Disord* 2000; 15: 48-55.
158. Caronti B, Tanda G, Colosimo C, et al. Reduced dopamine in peripheral blood lymphocytes in Parkinson's Disease. *NeuroReport* 1999; 10: 2907-10.
159. Arnold G, Bondy B, Bandmann O, et al. 3H-spiroperone binding to lymphocytes fails in the differential diagnosis of de novo Parkinson's Disease. *J Neural Transm* 1993; 5: 107-16.
160. Bellomo G, Santambrogio L, Fiacconi M, et al. Plasma profiles of adrenocorticotrophic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson's Disease. *J Neurol* 1991; 238: 19-22.
161. Espino A, Calopa M, Ambrosio S, et al. CSF somatostatin increase in patients with early parkinsonian syndrome. *J Neural Transm* 1995; 9: 189-96.
162. Jimenez-Jimenez FJ, Rubio JC, Molina JA, et al. Cerebrospinal fluid carnitine levels in patients with Parkinson's Disease. *J Neurol Sci* 1997; 145: 183-5.
163. Murofushi T, Mizuno M, Osanai R, et al. Olfactory dysfunction in Parkinson's Disease. *J Otorhinol Relat Spec* 1991; 53: 143-6.
164. Sakuma K, Nakashima K, Takahashi K. Olfactory evoked potentials in Parkinson's Disease, Alzheimer's disease, and anosmic patients. *Psychiatry Clin Neurosci* 1996; 50: 35-40.
165. Doty RL, Stern MB, Pfeiffer C, et al. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's Disease. *J Neurol Neurosurg Psychiatry* 1992; 55: 138-42.
166. Doty RL, Golbe LI, McKeown BA, et al. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's Disease. *Neurology* 1993; 43: 962-5.

167. Hawkes CH, Shephard BC. Olfactory evoked responses and identification tests in neurological disease. *Ann NY Acad Sci* 1998; 855: 608-15.
168. Potagas C, Dellatolas G, Ziegler M, et al. Clinical assessment of olfactory dysfunction in Parkinson's Disease. *Mov Disord* 1998; 13: 394-9.
169. Lehrner JP, Brucke T, Dal-Bianco P, et al. Olfactory functions in Parkinson's Disease and Alzheimer's Disease. *Chem Senses* 1997; 22: 105-10.
170. Montgomery EB, Koller WC, LaMantia TJK, et al. Early detection of probable idiopathic Parkinson's Disease: I. Development of a diagnostic test battery. *Mov Disord* 2000; 15: 467-73.
171. Montgomery EB, Lyons K, Koller WD. Early detection of probable idiopathic Parkinson's Disease: II. A prospective application of a diagnostic test battery. *Mov Disord* 2000; 15: 474-8.
172. Montgomery EB, Baker KB, Lyons K, et al. Abnormal performance on the PD test battery by asymptomatic first-degree relatives. *Neurology* 1999; 52: 757-62.
173. Rajput AH, Rozdilsky B, Ang L. Occurrence of resting tremor in Parkinson's Disease. *Neurology* 1991; 41: 1298-9.
174. Litvan I, MacIntyre A, Goetz CG, et al. Accuracy of the clinical diagnoses of Lewy Body Disease, Parkinson Disease, and dementia with Lewy bodies: A clinicopathologic study. *Arch Neurol* 1998; 55: 969-78.
175. Louis EK, Klatka LA, Liu Y, et al. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's Disease. *Neurology* 1997; 48: 376-80.
176. Wenning GK, Ebersbach G, Verny M, et al. Progression of falls in postmortem-confirmed parkinsonian disorders. *Mov Disord* 1999; 14: 947-50.
177. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's Disease patients. *Ann Neurol* 1997; 42: 747-55.
178. Allain H, Destee A, Petit H, et al. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's Disease. *Eur Neurol* 2000; 44: 22-30.
179. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. *J Neurol Neurosurg Psychiatry* 1997; 63: 421-8.
180. Kulisevsky J, Garcia-Sanches C, Berthier ML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's Disease. A two-year follow-up study of previously untreated patients. *Mov Disord* 2000; 15: 613-26.
181. Larsen JP, Boas J, Erdal JE, et al. Does selegiline modify the progression of early Parkinson's Disease? Results from a five-year study. *Eur J Neurol* 1999; 6: 539-47.
182. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's Disease: Results of a double-blind, placebo-controlled, parallel-group study. *Neurology* 1997; 49: 162-8.
183. Olanow CW, Fahn S, Muentner M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's Disease. *Mov Disord* 1994; 9: 40-7.
184. Kunig G, Pogarell O, Moller JC, et al. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's Disease. *Clin Neuropharmacol* 1999; 22: 301-5.
185. Steiger MJ, El-Debas T, Anderson T, et al. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. *J Neurol* 1996; 243: 68-72.

186. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's Disease. *Neurology* 1997; 49: 1060-5.
187. Martignoni E, Pachetti C, Sibilla L, et al. Dihydroergocryptine in the treatment of Parkinson's Disease: A six months' double-blind clinical trial. *Clin Neuropharmacol* 1991; 14: 78-83.
188. Olsson JE. Bromocriptine and levodopa in early combination in Parkinson's Disease: First results of the collaborative European multicentric trial. *Adv Neurol* 1990; 53: 421-3.
189. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's Disease: Efficacy and safety of long-term treatment. *Neurology* 1997; 49: 665-71.
190. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's Disease. *Neurology* 1996; 46: 1062-5.
191. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's Disease patients with motor fluctuations. *Neurology* 1996; 47: 785-8.
192. MacMahon DG, Overstall PW, Marshall T. Simplification of the initiation of bromocriptine in elderly patients with advanced Parkinson's Disease. *Age Ageing* 1991; 20: 146-51.
193. Rabey JM, Streifler M, Treves T, et al. The beneficial effect of chronic lisuride administration compared with levodopa in Parkinson's Disease. *Adv Neurol* 1990; 53: 451-5.
194. Wolters EC, Tesselaar HJ. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's Disease. *J Neurol* 1996; 243: 235-40.
195. Alarcon F. Does combined levodopa and bromocriptine therapy in Parkinson's Disease prevent late motor complications? *Eur J Neurol* 1998; 5: 255-63.
196. Bergamasco B, Frattola L, Muratorio A, et al. Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: Results of a multicentre, randomized, double-blind, placebo-controlled study. *Acta Neurol* 2000; 101: 372-80.
197. Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. *Acta Neurol Scand* 1996; 93: 14-20.
198. Koller WC, Hutton JT, Tolosa E, et al. Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study. *Neurology* 1999; 53: 1012-9.
199. Montastruc JL, Rascol O, Senard JM, et al. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's Disease: A five year follow up. *J Neurol Neurosurg Psychiatry* 1994; 57: 1034-8.
200. Myllyla VV, Sotaniemi KA, Vuorinen JA, et al. Selegiline as initial treatment in de novo parkinsonian patients. *Neurology* 1992; 42: 339-43.
201. Nappi G, Martignoni E, Horowski R, et al. Lisuride plus selegiline in the treatment of early Parkinson's Disease. *Acta Neurol Scand* 1991; 83: 407-10.
202. Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. *Neurology* 1998; 51: 520-5.
203. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's Disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. *Drugs* 1998; 55: 23-30.
204. Weiner WJ, Factor SA, Sanchez-Ramos JR, et al. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's Disease. *Neurology* 1993; 43: 21-7.

205. Hely MA, Morris JG, Reid WG, et al. The Sydney multicentre study of Parkinson's Disease: A randomised, prospective five-year study comparing low dose bromocriptine with low dose levodopa-carbidopa. *J Neurol Neurosurg Psychiatry* 1994; 57: 903-10.
206. Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's Disease. *Neurology* 1999; 53: 364-70.
207. Lees AJ, Parkinson's Disease Research Group in the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's Disease. *BMJ* 1995; 311: 1602-7.
208. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's Disease. *Ann Neurol* 1995; 38: 771-7.
209. Przuntek H, Welzel D, Gerlach M, et al. Early institution of bromocriptine in Parkinson's Disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. *J Neural Transm Park Dis Dement Sect* 1996; 103: 699-715.
210. Przuntek H, Conrad B, Dichgans J, et al. SELEDO: A 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa. *Eur J Neurol* 1999; 6: 141-50.
211. Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's Disease. *Ann Neurol* 1996; 40: 99-107.
212. Sethi KD, O'Brien CF, Hammerstad JP, et al. Ropinirole for the treatment of early Parkinson Disease: A 12-month experience. *Arch Neurol* 1998; 55: 1211-6.
213. Shannon KM, Bennett JPJ, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's Disease. *Neurology* 1997; 49: 724-8.
214. Bakheit AM, Henderson LM, Moore AP, et al. Long-term double masked trial of early treatment with L-dopa plus bromocriptine versus L-dopa alone in Parkinson's Disease. Interim results. *Eur Neurol* 1990; 30: 108-11.
215. Giminez-Roldan S, Tolosa E, Burguera JA, et al. Early combination of bromocriptine and levodopa in Parkinson's Disease: A prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. *Clin Neuropharmacol* 1997; 20: 67-76.
216. Nakanishi T, Iwata M, Goto I, et al. Nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Final report. *Eur Neurol* 1992; 32: 9-22.
217. Kleedorfer B, Poewe W. Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's Disease. Preliminary findings in 20 patients. *J Neural Transm [P-D Sect]* 1992; 4: 173-8.
218. Stocchi F, Bramante L, Monge A, et al. Apomorphine and lisuride infusion. A comparative chronic study. *Adv Neurol* 1993; 60: 653-5.
219. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's Disease. *Neurology* 1998; 51: 1057-62.
220. Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. *Neurology* 1998; 51: 1309-14.
221. de Bie RMA, de Haan RJ, Nijssen PCG, et al. Unilateral pallidotomy in Parkinson's Disease: A randomised, single-blind, multicentre trial. *Lancet* 1999; 354: 1665-9.
222. Young RF, Shumway-Cook A, Vermeulen SS, et al. Gamma knife radiosurgery as a lesioning technique in movement disorder surgery. *J Neurosurg* 1998; 89: 183-93.

223. Baron MS, Vitek JL, Bakay RAE, et al. Treatment of advanced Parkinson's Disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study. *Mov Disord* 2000; 15: 230-7.
224. Dalvi A, Winfield L, Yu Q, et al. Stereotactic posteroventral pallidotomy: Clinical methods and results at 1-year follow up. *Mov Disord* 1999; 14: 256-61.
225. Desaloms JM, Krauss JK, Lai EC, et al. Posteroventral medial pallidotomy for treatment of Parkinson's Disease: Preoperative magnetic resonance imaging features and clinical outcome. *J Neurosurg* 1998; 89: 194-9.
226. Dewey RB, Giller CA, Broline SK, et al. Clinical outcome of unilateral stereotactic pallidotomy without microelectrode recording for intractable Parkinson's Disease. *Parkinsonism Relat* 2000; 6: 7-16.
227. Dogali M, Sterio D, Fazzini E, et al. Effects of posteroventral pallidotomy on Parkinson's Disease. *Adv Neurol* 1996; 69: 585-90.
228. Eskandar EN, Shinobu LA, Penney JB, et al. Stereotactic pallidotomy performed without using microelectrode guidance in patients with Parkinson's Disease: Surgical technique and 2-year results. *J Neurosurg* 2000; 92: 375-83.
229. Herrera EJ, Viano JC, Caceres M, et al. Posteroventral pallidotomy in Parkinson's Disease. *Acta Neurochir (Wien)* 2000; 142: 169-75.
230. Iacono RP, Shima F, Lonser RR, et al. The results, indications, and physiology of posteroventral pallidotomy for patients with Parkinson's Disease. *Neurosurgery* 1995; 36: 1118-27.
231. Johansson F, Malm J, Nordh E, et al. Usefulness of pallidotomy in advanced Parkinson's Disease. *J Neurol Neurosurg Psychiatry* 1997; 62: 125-32.
232. Kondziolka D, Bonaroti E, Baser S, et al. Outcomes after stereotactically guided pallidotomy for advanced Parkinson's Disease. *J Neurosurg* 1999; 90: 197-202.
233. Lang AE, Lozano AM, Montgomery E, et al. Posteroventral medial pallidotomy in advanced Parkinson's Disease. *N Engl J Med* 1997; 337: 1036-42.
234. Masterman D, DeSalles A, Baloh RW, et al. Motor, cognitive, and behavioral performance following unilateral ventroposterior pallidotomy for Parkinson Disease. *Arch Neurol* 1998; 55: 1201-8.
235. Melnick ME, Dowling GA, Aminoff MJ, et al. Effect of pallidotomy on postural control and motor function in Parkinson Disease. *Arch Neurol* 1999; 56: 1361-5.
236. Roberts-Warrior D, Overby A, Jankovic J, et al. Postural control in Parkinson's Disease after unilateral posteroventral pallidotomy. *Brain* 2000; 123: 2141-9.
237. Samii A, Turnbull IM, Kishore A, et al. Reassessment of unilateral pallidotomy in Parkinson's Disease. A 2-year follow-up study. *Brain* 1999; 122: 417-25.
238. Samuel M, Caputo E, Brooks DJ, et al. A study of medial pallidotomy for Parkinson's Disease: Clinical outcome, MRI location and complications. *Brain* 1998; 121: 59-75.
239. Shannon KM, Penn RD, Kroin JS, et al. Stereotactic pallidotomy for the treatment of Parkinson's Disease. Efficacy and adverse effects at 6 months in 26 patients. *Neurology* 1998; 50: 434-8.
240. Taha JM, Favre J, Baumann TK, et al. Tremor control after pallidotomy in patients with Parkinson's Disease: Correlation with microrecording findings. *J Neurosurg* 1997; 86: 642-7.
241. Diederich N, Goetz CG, Stebbins GT, et al. Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's Disease. *Neurology* 1992; 42: 1311-4.
242. Fox MW, Ahlskog JE, Kelly PJ. Stereotactic ventrolateralis thalamotomy for medically refractory tremor in post-levodopa era Parkinson's Disease patients. *J Neurosurg* 1991; 75: 723-30.

243. Jankovic J, Hamilton WJ, Grossman RG. Thalamic surgery for movement disorders. *Adv Neurol* 1997; 74: 221-3.
244. Ardouin C, Pillon B, Peiffer E, et al. Bilateral subthalamic or pallidal stimulation for Parkinson's Disease affects neither memory nor executive functions: A consecutive series of 62 patients. *Ann Neurol* 1999; 46: 217-23.
245. Bejjani BP, Gervais D, Arnulf I, et al. Axial parkinsonian symptoms can be improved: The role of levodopa and bilateral subthalamic stimulation. *J Neurol Neurosurg Psychiatry* 2000; 68: 595-600.
246. Burchiel KJ, Anderson VC, Favre J, et al. Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's Disease: Results of a randomized, blinded pilot study. *Neurosurgery* 1999; 45: 1375-82.
247. Houeto JL, Damier P, Bejjani PB, et al. Subthalamic stimulation in Parkinson Disease: A multidisciplinary approach. *Arch Neurol* 2000; 57: 461-5.
248. Krack P, Pollak P, Limousin P, et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's Disease. *Brain* 1998; 121: 451-7.
249. Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's Disease. *N Engl J Med* 1998; 339: 1105-11.
250. Molinuevo JL, Valldeoriola F, Tolosa E, et al. Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson Disease. *Arch Neurol* 2000; 57: 983-8.
251. Koller W, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. *Ann Neurol* 1997; 42: 292-9.
252. Kumar K, Kelly M, Toth C. Deep brain stimulation of the ventral intermediate nucleus of the thalamus for control of tremors in Parkinson's Disease and essential tremor. *Stereotact Funct Neurosurg* 1999; 72: 47-61.
253. Limousin P, Speelman JD, Gielen F, et al. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. *J Neurol Neurosurg Psychiatry* 1999; 66: 289-96.
254. Goetz CG, Stebbins GE, Klawans HL, et al. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. *Neurology* 1991; 41: 1719-22.
255. Lopez-Lozano JJ, Bravo G, Abascal J, et al. Grafting of perfused adrenal medullary tissue into the caudate nucleus of patients with Parkinson's Disease. *J Neurosurg* 1991; 75: 234-43.
256. Velasco F, Velasco M, Rodriguez Cuevas H, et al. Autologous adrenal medullary transplants in advanced Parkinson's Disease with particular attention to the selective improvement in symptoms. *Stereotact Funct Neurosurg* 1991; 57: 195-212.
257. Henderson BT, Clough CG, Hughes RC, et al. Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's Disease. *Arch Neurol* 1991; 48: 822-7.
258. Kopyov OV, Jacques D, Lieberman A, et al. Clinical study of fetal mesencephalic intracerebral transplants for the treatment of Parkinson's Disease. *Cell Transplant* 1996; 5: 327-37.
259. Kopyov OV, Jacques DS, Lieberman A, et al. Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue. *Exp Neurol* 1997; 146: 536-45.
260. Lopez-Lozano JJ, Bravo G, Brera B, et al. Long-term improvement in patients with severe Parkinson's Disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-year follow up in 10 patients. *J Neurosurg* 1997; 86: 931-42.

261. Fink JS, Schumacher JM, Elias SL, et al. Porcine xenografts in Parkinson's Disease and Huntington's Disease patients: Preliminary results. *Cell Transplant* 2000; 9: 273-8.
262. Wermuth L, Sorensen PS, Timm B, et al. Depression in idiopathic Parkinson's Disease treated with citalopram. *Nord J Psychiatry* 1998; 52:163-9.
263. Sano M, Stern Y, Marder K, et al. A controlled trial of piracetam in intellectually impaired patients with Parkinson's Disease. *Mov Disord* 1990; 5: 230-4.
264. Factor SA, Brown D, Molho ES, et al. Clozapine: A two-year open trial in Parkinson's Disease patients with psychosis. *Neurology* 1994; 44: 544-6.
265. Kahn N, Freeman A, Juncos JL, et al. Clozapine is beneficial for psychosis in Parkinson's Disease. *Neurology* 1991; 41: 1699-700.
266. Rabey JM, Treves TA, Neufeld MY. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's Disease. *Neurology* 1995; 45: 432-4.
267. Ruggieri S, DePandis MF, Bonamartini A, et al. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's Disease. *Clin Neuropharmacol* 1997; 20: 204-9.
268. Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson's Disease: A retrospective analysis of a large multicentered clinical experience. *Mov Disord* 1998; 13: 377-82.
269. Wagner ML, Defilippi JL, Menza MA, et al. Clozapine for the treatment of psychosis in Parkinson's Disease: Chart review of 49 patients. *J Neuropsychiatry Clin Neurosci* 1996; 8: 276-80.
270. Meco G, Alessandri A, Giustini P, et al. Risperidone in levodopa-induced psychosis in advanced Parkinson's Disease: An open-label, long-term study. *Mov Disord* 1997; 12: 610-2.
271. Targum SD, Abbott JL. Efficacy of quetiapine in parkinson's patients with psychosis. *J Clin Psychopharmacol* 2000; 20: 54-60.
272. Dam M, Tonin P, Casson S, et al. Effects of conventional and sensory-enhanced physiotherapy on disability of Parkinson's Disease patients. *Adv Neurol* 1996; 69: 551-5.
273. Jahanshahi M, Brown RG, Whitehouse C, et al. Contact with a nurse practitioner: A short-term evaluation study in Parkinson's Disease and dystonia. *Behav Neurol* 1994; 7: 189-96.
274. Mally J, Stone TW. Improvement in parkinsonian symptoms after repetitive transcranial magnetic stimulation. *J Neurol Sci* 1999; 162: 179-84.
275. Mercer BS. A randomized study of the efficacy of the PROPATH program for patients with Parkinson's Disease. *Arch Neurol* 1996; 53: 881-4.
276. Montgomery EB, Lieberman A, Singh G, et al. Patient education and health promotion can be effective in Parkinson's Disease: A randomized controlled trial. *Am J Med* 1994; 97: 429-35.
277. Reynolds H, Wilson-Barnett J, Richardson G. Evaluation of the role of the Parkinson's Disease nurse specialist. *Int J Nurs Stud* 2000; 37: 337-49.
278. Patti F, Reggio A, Nicoletti F, et al. Effects of rehabilitation therapy on parkinsonians' disability and functional independence. *J Neuro Rehab* 1996; 10: 223-31.
279. Adams SG, Lang AE. Can the Lombard effect be used to improve low voice intensity in Parkinson's Disease? *Eur J Disord Commun* 1992; 27: 121-7.
280. Comella CL, Stebbins GT, Brown-Toms N, et al. Physical therapy and Parkinson's Disease: A controlled clinical trial. *Neurology* 1994; 44: 376-8.
281. DeAngelis EC, Mourao LF, Ferraz HB, et al. Effect of voice rehabilitation on oral communication of Parkinson's Disease

- patients. *Acta Neurol Scand* 1997; 96: 199-205.
282. Formisano R, Pratesi L, Modarelli FT, et al. Rehabilitation and Parkinson's Disease. *Scand J Rehab Med* 1992; 24: 157-60.
283. Katsikitis M, Pilowsky I. A controlled study of facial mobility treatment in Parkinson's Disease. *J Psychosom Res* 1996; 40: 387-96.
284. Nagaya M, Kachi T, Yamada T. Effect of swallowing training on swallowing disorders in Parkinson's Disease. *Scand J Rehab Med* 2000; 32: 11-5.
285. Pacchetti C, Mancini F, Agliere R, et al. Active music therapy in Parkinson's Disease: An integrative method for motor and emotional rehabilitation. *Psychosom Med* 2000; 62: 386-93.
286. Platz T, Brown RG, Marsden CD. Training improves the speed of aimed movements in Parkinson's Disease. *Brain* 1998; 121: 505-14.
287. Ramig LO, Countryman S, Thompson LL, et al. Comparison of two forms of intensive speech treatment for Parkinson's Disease. *J Speech Hear Res* 1995; 38: 1232-51.
288. Schenckman M, Cutson TM, Kuchibhatla M, et al. Exercise to improve spinal flexibility and function for people with Parkinson's Disease: A randomized, controlled trial. *J Am Geriatr Soc* 1998; 46: 1207-16.
289. Sitzia J, Haddrell V, Rice-Oxley M. Evaluation of a nurse-led multidisciplinary neurological rehabilitation programme using the Nottingham Health Profile. *Clin Rehabil* 1998; 12: 389-94.
290. Thaut MH, McIntosh GC, Rice RR, et al. Rhythmic auditory stimulation in gait training for Parkinson's Disease patients. *Mov Disord* 1996; 11: 193-200.
291. Pacchetti C, Aglieri R, Mancini F, et al. Active music therapy and Parkinson's Disease: Methods. *Funcy Neurol* 1998; 13: 57-67.
292. Smith ME, Ramig LO, Dromey C, et al. Intensive voice treatment in Parkinson's Disease: Laryngostroboscopic findings. *J Voice* 1995; 9: 453-9.
293. de Silva HAR, Khan NL, Wood NW. The genetics of Parkinson's Disease. *Curr Opin Genet Dev* 2000; 10: 292-8.
294. Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's Disease to chromosome 4q21-q23. *Science* 1996; 274: 1197-8.
295. Gasser T. Is Parkinson's Disease an inherited condition? *Adv Neurol* 1999; 80: 143-52.
296. Tanner CM, Ottman R, Golman SM, et al. Parkinson Disease in twins: an etiologic study. *JAMA* 1999; 281: 341-6.
297. Piccini P, Burn DJ, Ceravolo R, et al. The role of inheritance in sporadic Parkinson's Disease: Evidence from a longitudinal study of dopaminergic function in twins. *Ann Neurol* 1999; 45: 577-82.
298. Sveinbjornsdottir S, Hicks AA, Jonsson T, et al. Familial aggregation of Parkinson's Disease in Iceland. *N Engl J Med* 2000; 343: 1767-70.
299. Abbas N, Lucking CB, Ricard S, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. *Hum Mol Genet* 1999; 8: 567-74.
300. Hattori N, Kitada T, Matsumine H, et al. Molecular genetic analysis of a novel parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the parkin gene in affected individuals. *Ann Neurol* 1998; 44: 935-41.
301. Leroy E, Anastasopoulos D, Konitsiotis S, et al. Deletions in the parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's Disease. *Hum Genet* 1998; 103: 424-7.
302. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's Disease and mutations in the parkin gene. *N Engl J Med* 2000; 342: 1560-7.

- 303. Hu CJ, Sung SM, Liu HS, et al.
Polymorphisms of the parkin gene in
sporadic Parkinson's Disease among
Chinese in Taiwan. *Eur Neurol* 2000; 44:
90-3.
- 304. Freese A. Restorative gene therapy
approaches to Parkinson's Disease. *Med
Clin North Am* 1999; 83: 537-48.
- 305. Latchman DS. Herpes simplex virus vectors
for gene therapy in Parkinson's Disease and
other diseases of the nervous system. *J R
Soc Med* 1999; 92: 566-70.
- 306. Little RJA, Rubin DB. Statistical analysis
with missing data. New York: John Wiley &
Sons; 1987.